Dr. Tina Garyantes is the head of R&D at a clinical stage oncology company, Linnaeus Therapeutics, where she has overseen the advancement of their lead clinical asset from identification into Phase 2 clinical studies in under 3 years. Prior to Linnaeus, she led the therapeutics division of Chromocell where she advanced a non-opioid pain, neuroprotective, and anti-inflammatory molecule into the clinic and partnered it with Astellas Pharmaceuticals. She has over 25 years of pharmaceutical R&D experience at progressively more senior roles with cross functional teams of over 100 scientists. She has a broad therapeutic expertise based on strategic and leadership roles in multiple therapeutic areas. At Sanofi, she was responsible for reviewing project progression plans for all new targets and was on the leadership teams of several therapeutic areas. She has founded a company, developed and installed first of its kind instrumentation at the Mayo Clinic when at Chiron Diagnostics, and developed and out-licensed technology to Becton Dickenson when at Merck. She has also served on the boards of several biotechs and non-profits. Tina received her BSE in bioengineering from the University of Pennsylvania and her PhD in Biophysics from Caltech and has raised three young adults.